Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Gastric01: Rilvegostomig combinations vs pembrolizumab-based standard care in first-line HER2-positive gastric/GEJ cancer
jRCT2031250011Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised trial of rilvegostomig in Gastric cancer (HER2-positive) and gastroesophageal junction adenocarcinoma (3 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Overall survival. Started May 2025; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
Gastric cancer (HER2-positive)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031250011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250011.